source
- INBRX-106 plus pembrolizumab shows higher response rate than pembrolizumab alone in first-line PD-L1-positive head-and-neck cancerThe HexAgon-HN trial evaluated the OX40 agonist INBRX-106 combined with pembrolizumab in patients with treatment-naive, PD-L1‑positive metastatic or unresectable head‑and‑neck squamous cell carcino…
- ctDNA testing shows promise for renal cell carcinoma and germ cell tumors despite current limitationsExperts discussed how circulating tumor DNA (ctDNA) monitoring, long used in bladder cancer, is being explored for renal cell carcinoma (RCC) and germ cell tumors. In RCC, low tumor shedding has l…